{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:30:32Z","timestamp":1784086232401,"version":"3.55.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In the management of Peripheral Arterial Disease (PAD), the administration of anticoagulant or antiplatelet agents is imperative. The use of Dual Antiplatelet Therapy (DAPT) in conjunction with rivaroxaban has shown potential in mitigating adverse outcomes. Given the heterogeneity in the pathology of lower limb arteries, there is a compelling case for individualized treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a single-center retrospective study on pharmacotherapy for peripheral artery disease, patients were treated with either aspirin combined with rivaroxaban or aspirin coupled with clopidogrel. The primary efficacy outcome encompassed a composite of increases in the Rutherford classification, acute limb ischemia, amputations due to vascular causes, target lesion revascularization, myocardial infarction, ischemic stroke, and cardiovascular death. The primary safety outcome was major bleeding, as defined by the Thrombolysis in Myocardial Infarction (TIMI) criteria; meanwhile, major bleeding as categorized by the International Society on Thrombosis and Haemostasis (ISTH) served as a secondary safety outcome. The study differentiated between two subgroups: patients with only above-the-knee and below-the-knee arterial lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From January 2016 to December 2021, 455 patients received either clopidogrel plus aspirin or rivaroxaban plus aspirin following endovascular treatment (EVT). The rivaroxaban group (<jats:italic>n<\/jats:italic>\u2009=\u2009220) exhibited a lower incidence of primary efficacy outcomes [49.1% vs. 60.4%, hazard ratio (HR) 0.77, <jats:italic>P<\/jats:italic>\u2009=\u20090.006] but had more TIMI major bleeding events (5.9% vs. 2.1%, HR 2.6, <jats:italic>P<\/jats:italic>\u2009=\u20090.04). ISTH major bleeding events did not show a significant difference, though a higher percentage of rivaroxaban patients discontinued medication due to bleeding (10% vs. 4.7%, HR 2.2, <jats:italic>P<\/jats:italic>\u2009=\u20090.03). In the above-the-knee arterial disease subgroup, the rivaroxaban group demonstrated a lower incidence of primary efficacy outcomes (28.2% vs. 45.2%, HR 0.55, <jats:italic>P<\/jats:italic>\u2009=\u20090.02). In the below-the-knee arterial disease subgroup, no significant difference was observed in the occurrence of primary efficacy events between the two groups (58.7% vs. 64.8%, HR 0.76, <jats:italic>P<\/jats:italic>\u2009=\u20090.14).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Rivaroxaban plus aspirin improved outcomes compared to DAPT in patients with lower extremity artery disease. Similar findings were observed in the above-the-knee artery lesion-only group. However, in the below-the-knee artery lesion-only group, rivaroxaban plus aspirin did not surpass DAPT in efficacy. Regarding safety, rivaroxaban plus aspirin exhibited higher bleeding risks and more frequent treatment discontinuation than aspirin combined with clopidogrel.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2023.1285553","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T03:39:22Z","timestamp":1699846762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions"],"prefix":"10.3389","volume":"10","author":[{"given":"SiYan","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","article-title":"Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry","volume":"35","author":"Kumbhani","year":"2014","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European stroke organization (ESO) The task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1161\/CIR.0000000000000470","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.jcin.2016.07.034","article-title":"Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2\u00b0P-TIMI 50 trial","volume":"9","author":"Bonaca","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/CIRCULATIONAHA.119.039773","article-title":"Acute limb ischemia in peripheral artery disease","volume":"140","author":"Hess","year":"2019","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jacc.2018.06.041","article-title":"Major adverse limb events and 1-year outcomes after peripheral artery revascularization","volume":"72","author":"Hess","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.116.025880","article-title":"Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease","volume":"135","author":"Jones","year":"2017","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jacc.2019.11.050","article-title":"Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization","volume":"75","author":"Hess","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"B11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.recesp.2017.12.015","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS)","volume":"71","author":"Aboyans","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","article-title":"Combination antithrombotic therapies","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2215580","DOI":"10.1001\/jamanetworkopen.2022.15580","article-title":"Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization","volume":"5","author":"Hess","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.118.033580","article-title":"Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease","volume":"139","author":"Gurbel","year":"2019","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCINTERVENTIONS.111.962324","article-title":"Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month zilver PTX randomized study results","volume":"4","author":"Dake","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCINTERVENTIONS.109.903468","article-title":"Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial","volume":"3","author":"Laird","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jcin.2013.07.010","article-title":"Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery)","volume":"6","author":"Liistro","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s00330-007-0593-2","article-title":"Endovascular optical coherence tomography ex vivo: venous wall anatomy and tissue alterations after endovenous therapy","volume":"17","author":"Meissner","year":"2007","journal-title":"Eur Radiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.jacc.2018.08.002","article-title":"Pathology of peripheral artery disease in patients with critical limb ischemia","volume":"72","author":"Narula","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/j.jacc.2018.08.2145","article-title":"Pathology of arterial disease in limb loss: the clot thickens","volume":"72","author":"Creager","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ahj.2010.04.022","article-title":"Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina\/non-ST-segment elevation myocardial infarction: the targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes (TRILOGY ACS) trial","volume":"160","author":"Chin","year":"2010","journal-title":"Am Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jacc.2011.01.011","article-title":"The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents","volume":"57","author":"Nakazawa","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jcin.2011.05.025","article-title":"Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis","volume":"4","author":"Inoue","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1046\/j.1538-7836.2003.00298.x","article-title":"What is all that thrombin for?","volume":"1","author":"Mann","year":"2003","journal-title":"J Thromb Haemost"},{"key":"B33","first-page":"675","article-title":"Response to injury and atherogenesis","volume":"86","author":"Ross","year":"1977","journal-title":"Am J Pathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMra1011670","article-title":"The hemostatic system as a modulator of atherosclerosis","volume":"364","author":"Borissoff","year":"2011","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"13729","DOI":"10.1074\/jbc.M400150200","article-title":"Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells","volume":"279","author":"Shimizu","year":"2004","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molmed.2008.08.001","article-title":"Factor Xa: at the crossroads between coagulation and signaling in physiology and disease","volume":"14","author":"Borensztajn","year":"2008","journal-title":"Trends Mol Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.actbio.2019.03.053","article-title":"Mechanical damage characterization in human femoropopliteal arteries of different ages","volume":"90","author":"Anttila","year":"2019","journal-title":"Acta Biomater"},{"key":"B38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/ncn3.12542","article-title":"Direct aspiration through a balloon guide catheter can augment vessel wall injury","volume":"9","author":"Inoue","year":"2021","journal-title":"Neurol Clin Neurosci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1161\/01.CIR.95.8.1998","article-title":"Histopathology of in-stent restenosis in patients with peripheral artery disease","volume":"95","author":"Kearney","year":"1997","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehaa049","article-title":"Compare: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions","volume":"41","author":"Steiner","year":"2020","journal-title":"Eur Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1526602818760488","article-title":"Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial","volume":"25","author":"Moll","year":"2018","journal-title":"J Endovasc Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1016\/j.ejrad.2012.12.021","article-title":"Foot CT perfusion in patients with peripheral arterial occlusive disease (PAOD): a feasibility study","volume":"82","author":"Iezzi","year":"2013","journal-title":"Eur J Radiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJM200105243442108","article-title":"Medical treatment of peripheral arterial disease and claudication","volume":"344","author":"Hiatt","year":"2001","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4244\/EIJV7I9A178","article-title":"Tools & techniques: below the knee interventions","volume":"7","author":"Sauguet","year":"2012","journal-title":"EuroIntervention"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.3390\/jcm9103321","article-title":"Infrapopliteal artery occlusive disease: an overview of vessel preparation and treatment options","volume":"9","author":"Tummala","year":"2020","journal-title":"J Clin Med"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2023.1285553\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T03:39:25Z","timestamp":1699846765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2023.1285553\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":46,"alternative-id":["10.3389\/fsurg.2023.1285553"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2023.1285553","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"article-number":"1285553"}}